Navigation Links
Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
Date:10/20/2009

1:00 p.m. Eastern Time through October 22, 2009 at 11:59 p.m. To access the replay, dial 1 (888) 266- 2081 and enter pass code 1405084.

About Novavax

Novavax is a clinical-stage biotechnology company creating novel vaccines to address a

broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. It recently launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the 2009 H1N1 vaccine, the potential use of any data from clinical trials and other anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including clinical trial results, which may not be sufficient for regulatory approval or may indicate safety concerns not yet encountered; even if the results of the planned clinical trial are positive, the data may not be accepted by regulatory bodies in other countries or the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; if approved, approval of
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
2. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
3. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
4. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
5. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
6. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
7. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
8. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
9. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... OAKS, Calif., July 29, 2014 Amgen (NASDAQ: ... the second quarter of 2014. Key results include: ... with 8 percent product sales growth driven by strong ... Kyprolis ® (carfilzomib), Prolia ® (denosumab) and ... 25 percent to $2.37, driven by higher revenues and ...
(Date:7/29/2014)... RIDGE, N.J. , July 29, 2014 ... biopharmaceutical company focused on the Phase 3 clinical development ... actively controllable antithrombotic drug system, today announced that it ... on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT ... corporate highlights. Interested participants and investors may ...
(Date:7/29/2014)... ST. PAUL, Minn. , July 29, 2014 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... Conference Call Details The second quarter conference ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
...   Delcath Systems, Inc. (NASDAQ: DCTH ) ... Board. "As a widely respected hepatologist ... (ILCA), Dr. Gores will contribute a wealth of clinical ... our Medical Advisory Board," said Eamonn P. Hobbs, CEO ...
... PLEASANTON, Calif., Dec. 21, 2011  TriReme Medical, Inc. ... the treatment of complex vascular disease, announced today ... U.S. Food and Drug Administration to market its ... of occluded peripheral arteries. Chocolate was developed in ...
Cached Medicine Technology:Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4TriReme Medical, Inc. Receives FDA 510(K) Clearance for Chocolate PTA Balloon Catheter 2
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent of people ... condition which occurs most frequently in people between the ages ... and half years if not treated. , Adhesive capsulitis is ... it can render your shoulder so stiff, it's almost impossible ... in too much pain to get dressed in the first ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Young adults who were breastfed for three months ... risk of chronic inflammation associated with cardiovascular and ... School at Washington University in St. Louis. , ... have implications for children,s health decades later," said ... Brown School and a co-author of the study ...
(Date:7/30/2014)... 30, 2014 Everyone knows that the internet ... everyone. Whether people are looking for something to buy, trying ... dentist, the internet is pretty much always going to be ... in Lauderdale Florida is so happy to announce the launch ... presence into the modern age. Whether a person wants to ...
(Date:7/30/2014)... The North America aviation actuator market is ... America is expected to be the fastest growing region ... of 5.60%. , The commercial aircraft market offers ... assume prominence in the years to come. Commercial aviation ... has regained quickly, and the industry has been reliably ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
... , FRIDAY, Aug. 5 (HealthDay News) -- Believing in a ... ability to cope with uncertainty, researchers report. The paper, ... includes the results of two studies conducted by researchers at ... study of 332 Christians and Jews found that those who ...
... -- Smoking increases the risk of developing a heart rhythm ... researchers reviewed data from more than 15,000 people, aged 45 ... years, and found that there were 876 atrial fibrillation events ... rhythm was 1.32 times higher in former smokers and two ...
... FRIDAY, Aug. 5 (HealthDay News) -- For older Americans who ... that performance often trumps appearance. The boost in body ... exercise proved more satisfying than any change in appearance, especially ... advancing years, a shift in emphasis may occur, one that ...
... News) -- Children with HIV who receive antiretroviral treatments ... levels, and would benefit from guidelines aimed at reducing ... are published in JAIDS: Journal of Acquired Immune ... crucial step in minimizing cardiovascular disease complications and maximizing ...
... of Sexual Medicine reveals that in obese men ... sexual desire and lowers urinary tract symptoms. Researchers ... of the University of Adelaide studied 31 obese men ... received either a meal replacement-based low-calorie diet or a ...
... available in Spanish . , ANN ARBOR, Mich. ... can be used safely and effectively even in tumors from ... from the University of Michigan Comprehensive Cancer Center. Sentinel ... the first node where cancer would likely spread. If that ...
Cached Medicine News:Health News:Less Worry, Better Coping Seen Among Religious Folks 2Health News:With Age, Focus on Body Shifts From Appearance to Function 2Health News:With Age, Focus on Body Shifts From Appearance to Function 3Health News:Children's HIV Drugs May Cause High Cholesterol 2Health News:Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: